Qiagen


2025 ended positively, entering 2026 with confidence

06/02/26 -"Qiagen’s Q4 results surpassed both market expectations and management’s guidance, with most segments reporting gains. The 2026 guidance aligns with expectations, and the firm’s ..."

Pages
64
Language
English
Published on
06/02/26
You may also be interested by these reports :
06/02/26
Qiagen’s Q4 results surpassed both market expectations and management’s guidance, with most segments reporting gains. The 2026 guidance aligns with ...

05/02/26
GN’s Q4 results fell short of market expectations. While Hearing experienced healthy growth, this was overshadowed by weaknesses in Gaming and ...

05/02/26
Our estimates have been moderated following the Q4 25 miss, primarily reflecting a softer order book and growth momentum (especially for the LS ...

05/02/26
Siemens Healthineers’ Q1 profitability exceeded the company-compiled consensus. While sales rose in Q1, growth was limited due to weakness in China. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO